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types and organs, describing the potential mechanisms of action 
and biological roles of GlyRs in these cell types.
NEUROGLIAL CELLS
Ontogenetically, neuroglial cells in the CNS can be divided into ecto-
dermal-derived macroglial cells (oligodendrocytes and astrocytes) 
and mesodermal-derived microglial cells. Macroglial cells have the 
same embryonic origin as neurons. The fi rst reports of neurotrans-
mitter receptors in oligodendrocytes and astrocytes suggested that 
no functional GlyRs were present on these cell types (Gilbert et al., 
1984; Kettenmann et al., 1984a,b). However, ionotropic GABA
A
 
receptors were detected, which mediate depolarizing currents 
upon ligand binding. This depolarization is explained by GABA-
induced chloride effl ux, due to the expression of the Na+–K+–Cl− 
co-transporter (NKCC1) leading to a high intracellular chloride 
concentration and, hence, to a less negative Nernst potential for 
chloride (Hoppe and Kettenmann, 1989; Kettenmann et al., 1987). 
Around ten years later, molecular and functional studies demon-
strated that macroglial cells harbour functional α1β GlyRs when 
studied ex vivo in spinal cord slices (Kirchhoff et al., 1996; Pastor 
et al., 1995). The apparent contradiction with previous in vitro 
studies may be related to cell culture conditions, which might lead 
to GlyR down regulation. In this context, excess glycine in certain 
types of cell culture medium has previously been linked to cell death 
in heterologous GlyR expression experiments (Groot-Kormelink 
et al., 2002). Nguyen and Belachew further demonstrated, in their 
oligodendrocyte and neurosphere models, that both GlyRs and 
glycine transporters (GlyTs) were molecularly and functionally 
present at different stages of macroglial development (Belachew 
et al., 1998a,b, 2000; Nguyen et al., 2002). In oligodendrocyte pro-
genitors, glycine was found to depolarize the cell membrane, via the 
activation of both GlyRs and GlyTs. This depolarization led to the 
INTRODUCTION
Glycine is one of the main components that mediate fast inhibitory 
neurotransmission in the central nervous system (CNS). Whilst 





Rs) acts on the rostral part, glycine-mediated 
transmission operates in the caudal part of the CNS (brain stem 
and spinal cord). Activation of glycine-gated ion channels (GlyRs) 
leads to postsynaptic hyperpolarization induced by chloride infl ux, 
or a shunt effect characterized by a drop in membrane resistance 
consecutive to enhanced chloride conductance. GlyRs are penta-
meric proteins belonging to the cys-loop family of ligand-gated 
ion channels. GlyRs are able to form homomeric receptors, com-
posed of α subunits, or heteromeric receptors, composed of α and 
of β-subunits and in a putative 3β/2α or 2β/3α stoichiometry 
(Grudzinska et al., 2005). Four different subtypes of α (α1–α4) 
and one β subunit, encoded by separate genes, have been described 
to date in most species. GlyRs are typically considered to consist of 
α1β-heteromers in the mature spinal cord and brainstem, whilst in 
the foetal/neonatal nervous system homomeric α2 subunit GlyRs 
are suggested to predominate (for reviews see Betz and Laube, 2006; 
Kirsch, 2006; Legendre, 2001; Lynch, 2004). However, the GlyR α3 
subunit has recently emerged as a key players in infl ammatory pain 
pathways in the spinal cord dorsal horn (Harvey et al., 2004), and it 
is clear that we do not yet know the full extent of locations and cell 
types expressing GlyRs. Increasing evidence suggests that inhibi-
tory neurotransmitters, including glycine, exert a more general 
signalling role than the pure transmission of neuronal inhibition, 
both within and outside the nervous system. In this respect, it is 
important to note that GABA and glycine play a key role in devel-
opmental processes in neural stem cells and progenitors (reviewed 
in Nguyen et al., 2001). In this review we focus on non-synaptic 
roles of glycine and GlyR-mediated signalling in non-neuronal cell 
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activation of voltage-gated calcium  channels (VGCCs) and, hence, 
calcium infl ux. This calcium infl ux may be one of the crucial sig-
nals in the development of oligodendroglial cells. GlyT1 and GlyRs 
containing the α1 and β subunits were also described in retinal 
Müller cells. In these cells, glycine was shown to have a depolar-
izing effect, suggesting an important signalling role in potassium 
siphoning, or in the regulation of synaptic glycine concentrations 
(Du et al., 2002; Lee et al., 2005). Our group also found molecular 
evidence for GlyR expression in different oligodendroglial cell lines 
(MO3.13, OLN-93, HOG), although the receptors appear to show 
a cytoplasmic location, which might explain why we could not 
detect any GlyR-mediated ionic currents (Sahebali et al., 2007). In 
this respect, Nguyen et al. also found a discrepancy between the 
number of cells that express GlyRs (80%) and those that exhibit 
glycine-induced currents (33%; Nguyen et al., 2002). A cytoplas-
mic location for GlyRs has previously been described in spinal 
cord neurons (Bechade et al., 1996) and although little is known 
about GlyR traffi cking, it was shown that GlyRs can be ubiquiti-
nated, causing receptor internalization and proteolysis (Buttner 
et al., 2001). Also chronically blocking GlyR activity with strych-
nine (1–10 µM) was demonstrated to cause receptor internaliza-
tion (Levi et al., 1998). Since glycine-gated currents are detected 
in tissue slices while they are absent in individual cell cultures, one 
could speculate that GlyRs are present in macroglial cells, but that 
their plasma membrane location and, hence, their functionality is 
dependent upon cell  culture conditions. It seems indeed likely that 
some unknown factor(s) in the normal physiological environment 
of slices might be necessary for plasma membrane expression of 
GlyRs. Further research is however necessary to identify this (these) 
factor(s). Downstream events of such factor(s) could at least imply 
protein kinase activity. In that respect, it has been shown that, in the 
retina and in auditory nuclei, protein kinases modulate strychnine 
binding and, hence, GlyR expression (Salceda and Aguirre-Ramirez, 
2005; Yan et al., 2007). Figure 1 summarizes the current fi ndings on 
glycine and GlyR signalling in macroglial cells. Glycine transport-
ers, astrocytic GlyT1 as well as presynaptic neuronal GlyT2 are of 
utmost importance for correct glycine recycling both at glutama-
tergic and at glycinergic synapses, but fall beyond the scope of this 
review (see Aragon and Lopez-Corcuera, 2003).
Microglial cells, although of mesodermal origin, are considered 
here because of their intimate spatial relationships to other glial 
cells and neurons. Over ten years ago, key studies showed that 
astrocyte-derived glycine and l-serine (between 10 and 100 µM) 
modulate microglial activity. Micromolar concentrations of glycine 
induced morphological changes in microglial cells and enhanced 
lipopolysaccharide (LPS)-induced secretion of nitrogen oxide 
(NO), superoxide, acid phosphatase as well as metabolic activity. 
These studies, however, did not focus on the mechanism of this 
FIGURE 1 | Glycine signalling in macroglial cells. In macroglial cells, 
NKCC activity leads to intracellular chloride accumulation. Upon ligand 
binding, GlyR activation causes chloride effl ux leading to cellular depolarization 
(which is further enhanced by electrogenic GlyT activity). This depolarization 
then activates VGCC. The resulting calcium infl ux increases the intracellular 
calcium concentration inducing several downstream effects 
(e.g. cell proliferation, migration and differentiation). Endocytosis of 
GlyRs might inactivate these receptors, explaining discrepancies between 
molecular and functional fi ndings. Although cell culture conditions appear 
to have an infl uence on GlyR functionality and possibly endocytosis, 
the molecular mechanisms regulating of GlyR endocytosis are 
unknown.
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modulatory  activity (Tanaka et al., 1998; Yang et al., 1998). Since 
glycine effects could be mimicked by l-serine, a metabolic precur-
sor of glycine, and since microglial cells were shown to have a low 
expression of 3-phosphoglycerate dehydrogenase, a key enzyme 
in l-serine and, hence, glycine biosynthesis, it was suggested that 
glycine and l-serine could be essential amino acids for micro-
glial cells (Sugishita et al., 2001). This would have implied that 
the above-mentioned effects could be explained by a metabolic 
mechanism. This is however contradicted by the high glycine and 
l-serine synthesis capacities of microglial cells, which seem able to 
produce glycine and l-serine at concentrations of 88 and 144 µM, 
respectively (Hayashi et al., 2006). Another study by Schilling and 
Eder demonstrated that glycine can depolarize BV-2 microglial 
cells. Glycine-induced currents were insensitive to strychnine 
(1 µM) or GlyT-antagonists, were chloride-independent and could 
not be mimicked by the GlyR agonist taurine. Based upon the 
sodium dependency of glycine currents, their blockade by MeAIB 
(α-(methylamino)isobutyric acid), the agonist effect of glutamine 
and their low amplitude, the authors concluded that system A neu-
tral amino acid transporters (SNATs) were responsible for these 
currents. Moreover, they suggested that these currents, although 
small, could have a signalling role via membrane depolarization 
(Schilling and Eder, 2004). Indeed, glycine-induced depolariza-
tion was substantial (up to +30 mV) despite the low amplitude of 
the currents (around 10 pA), and could be explained by the high 
membrane resistance of microglial cells (Newell and Schlichter, 
2005). Although these data suggest that functional GlyRs are not 
present on microglial cells, our group recently provided molecular 
evidence for α and β GlyR subunit and gephyrin expression in these 
cells (J. Van den Eynden, unpublished results). However, the role 
of these GlyRs remains elusive. Indeed, we also confi rmed that the 
above-mentioned fi ndings in microglial cells were GlyR-independ-
ent (Van den Eynden et al., 2008). By analogy with macroglial cells, 
the discrepancy between molecular and functional data might be 
explained by cell culture conditions and/or GlyR down-regulation. 
Future research on brain or spinal cord slices and GlyR traffi cking 
will be necessary to examine this hypothesis.
CONCLUSION
Astrocytes, oligodendrocytes and microglial cells are intimate part-
ners of neurons in the neuronal microenvironment. GlyRs (and 
GlyTs) have been described on different developmental stages of 
macroglial cells where they may have a developmental role in the 
immature CNS, as well as a communication function in the mature 
CNS. Glycine signalling in microglial cells may be mediated by 
non-specifi c amino acid transporters. However, the biological and 
functional role(s) of microglial GlyRs remain unknown.
IMMUNE CELLS
In recent years, it has become obvious that glycine has immu-
nomodulatory effects on different immune cells. As a common 
feature, inhibition of immune function was found in most in vitro 
studies, explaining the benefi cial effects of glycine that were found 
in animal studies. For reviews on glycine immunomodulatory 
effects, the reader can also consult (Wheeler et al., 1999; Zhong 
et al., 2003). Glycine effects on immune cells have been mainly stud-
ied in macrophages, in particular using Kupffer cells, the resident 
macrophages of the liver. When rat were fed with a diet containing 
5% glycine for 3 days and then subjected to intravenous LPS injec-
tion (an animal model of endotoxic shock), a signifi cant decrease in 
mortality, liver necrosis, lung damage and serum tumour necrosis 
factor α (TNFα) levels were found (Ikejima et al., 1996). These 
benefi cial effects were mainly attributed to the inhibitory effects 
of glycine on Kupffer cells. It was also shown that glycine (0.1–
1 mM) blunted LPS-induced calcium fl uxes in Kupffer cells, an 
effect that could be reversed by low concentrations of strychnine 
(1 µM) and that was not present when a chloride-free buffer was 
used. Furthermore, glycine was also able to induce uptake of 36Cl− 
by Kupffer cells (Froh et al., 2002; Ikejima et al., 1996, 1997), an 
effect that could be mimicked by taurine and β-alanine, two GlyR 
agonists (Seabra et al., 1998). These fi ndings clearly suggest a role 
for GlyRs in modulating Kupffer cell functions. Since fl uorimetric 
measurements showed that LPS depolarized Kupffer cells while 
glycine hyperpolarized them, it was suggested that GlyR-depend-
ent hyperpolarization leads to an inhibition of functional VGCC, 
which were also found in Kupffer cells (Hijioka et al., 1992). More 
recently, glycine was shown to inhibit Toll-like receptor 4 upregula-
tion after LPS exposure in Kupffer cells, showing that other signal-
ling pathways may operate in these cells (Xu et al., 2008). Finally, 
GlyR α1, α4 and β subunit transcripts and proteins were detected 
in Kupffer cells (Froh et al., 2002). All the above-described gly-
cine effects on Kupffer cells may explain why glycine is benefi cial 
when co-administered in d-galactosamine and ethanol-induced 
hepatotoxicity models (Bruck et al., 2003; Stachlewitz et al., 1999; 
Yamashina et al., 2005). It was indeed shown that ethanol increases 
gut permeability and hence endotoxine uptake, leading to Kupffer 
cell activation and secretion of cytokines (e.g. TNFα), responsible 
for liver toxicity (Wheeler, 2003). In alveolar macrophages, glycine 
was also found to blunt calcium fl uxes, to increase 36Cl− uptake 
and to decrease superoxide and TNFα secretion. The sensitivity of 
alveolar macrophages to glycine was higher than for Kupffer cells 
(IC
50
 ≈10 µM, versus ≈300 µM in Kupffer cells). One suggestion 
for this fi nding was that, due to the lower alveolar extracellular 
glycine concentration, there might be less GlyR down-regula-
tion and, hence, a higher GlyR density on alveolar macrophages 
(Wheeler and Thurman, 1999). This hypothesis was confi rmed by 
animal studies where rats were fed on a glycine-rich diet for 4 weeks. 
After this period, Kupffer cells had lost their glycine responsive-
ness, while alveolar macrophages had not, further suggesting GlyR 
down-regulation after chronic exposure to glycine (Wheeler et al., 
2000b). In splenic macrophages similar effects on calcium fl uxes 
and chloride-uptake were observed (Li et al., 2001). Finally, molecu-
lar evidence for GlyR α2, α4 and β subunits was found in alveolar 
and splenic macrophages (Froh et al., 2002). Next to macrophages, 
also studies concerning glycine effects on other immune cells were 
conducted. In T lymphocytes, there is confl icting evidence regard-
ing the modulatory role of glycine. Glycine was suggested to have 
anti-apoptotic effects on MOLT4 cells, a human T lymphoblastic 
leukaemia cell line, at millimolar concentrations (Franek et al., 
2002). Stachlewitz found that glycine dose-dependently inhibited 
proliferation of rat lymphocytes between 0.1 and 1 mM and blunted 
concanavalin A induced calcium fl uxes. This latter effect could be 
blocked by strychnine (1 µM) or by replacing chloride by gluco-
nate, suggesting the involvement of GlyRs (Stachlewitz et al., 2000). 
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The authors hypothesized that GlyR activation hyperpolarized the 
cells, leading to inhibition of VGCCs. However, this is in contradic-
tion with the high chloride concentration (30–60 mM) reported 
in lymphocytes, which, together with the reported membrane 
potential of −50 to −70 mV, should lead to depolarization upon 
GlyR activation (Pilas and Durack, 1997; Tian et al., 1999). The 
putative implication of VGCCs in lymphocytes is also controversial 
since calcium-release-activated calcium channels (CRACs) seem to 
be far more important for lymphocyte activation (for review see 
Lewis, 2001). Alternatively, we suggest that these inhibiting effects 
on calcium fl uxes could arise from membrane depolarization 
induced by a GlyR-mediated chloride effl ux. This depolarization 
would cause both a decrease in the calcium electrical gradient and 
a decrease in CRAC channel conductance, leading to lower CRAC-
mediated calcium infl ux. This mechanism was already suggested 
to explain GABA
A
R-mediated inhibitory effects on calcium fl uxes 
in T lymphocytes (Alam et al., 2006; Tian et al., 1999). The inhibi-
tory effects of glycine on rat lymphocyte proliferation (Stachlewitz 
et al., 2000) are in contradiction with other studies suggesting that 
(i) glycine does not infl uence mitogen-induced proliferation of 
human peripheral blood mononuclear cells (PBMCs) (Sommer 
et al., 1994) and (ii) that glycine does not modulate N-formyl-
methionyl-leucyl-phenylalanine (fMLP)- or LPS-induced calcium 
fl uxes in human PBMCs (Alam et al., 2006). A feasible explanation 
for these apparently confl icting results may be interspecies differ-
ences in GlyR expression. In this respect, it is interesting to note 
that most immune cells studied so far, including T-lymphocytes 
(J. Van den Eynden, unpublished results) appear to express the 
GlyR α4 subunit (Alam et al., 2006; Froh et al., 2002). In human, 
GLRA4 is a pseudogene due to the presence of a premature stop 
codon in exon 9, which could explain the absence of functional 
GlyRs in human studies (Simon et al., 2004). Finally, neutrophils 
also seem to express functional GlyRs. In these cells, glycine inhib-
its LPS- and fMLP-induced calcium fl uxes, increases 36Cl− uptake 
and decreases superoxide production, all effects that were blocked 
by 1 µM strychnine (Wheeler et al., 2000a). Rat neutrophils also 
appear to express GlyR α2, α4 and β subunits (Froh et al., 2002). In 
human monocytes, glycine was found to inhibit LPS-induced TNFα 
and interleukin (IL)-1 secretion and to enhance IL10 secretion, 
effects that were strychnine sensitive (1 µM; Spittler et al., 1999). 
Using fl ow cytometry, we have also found evidence for GlyR α2 
subunit expression in human monocytes and in natural killer cells, a 
cell population where glycine effects were not studied to date (R. J. 
Harvey and N. J. Horwood, Figure 2).
CONCLUSION
Effects of glycine were demonstrated on most immune cells. On 
monocytes, macrophages and neutrophils, glycine inhibits calcium 
fl uxes leading to a decreased secretion of cytokines (e.g. TNFα). 
These effects are likely to be mediated by functional GlyRs, although 
there may be important species differences in subunit composition. 
Glycine also seems to exert immunomodulatory effects in T lym-
phocytes, although, in this case, the results are less clear cut.
RENAL CELLS
In the kidney, several in vitro studies point to cytoprotective effects 
of glycine against ischemia. The fi rst evidence of such a protective 
role of glycine came from a study showing that glycine, produced 
by the metabolism of glutathione (rather than glutathione itself, as 
previously thought, Paller, 1986), protects isolated proximal tubules 
against ischemia in a concentration range of 0.25–2 mM (Weinberg 
et al., 1987). Since hypoxic conditions lead to a decrease of β-oxi-
dation and, hence, to an increase in acyl-coenzyme A which, in 
turn, may lead to detergent-like membrane damage, it was initially 
suggested that glycine effects could be explained by acylglycine 
formation and, hence, metabolic detoxifi cation. However, it was 
subsequently shown that this metabolic mechanism plays no major 
role in glycine-induced cytoprotection (Weinberg et al., 1991a). It 
FIGURE 2 | Human monocytes and NK cells express GlyR α2 subunits. 
Human peripheral blood mononuclear cell subsets were evaluated for the 
expression of GlyR α2 using a rabbit anti human GlyR α2 antibody (FITC) and 
either mouse anti-human CD3 (APC), mouse anti-human CD14 (PE) or mouse 
anti-human CD56 (PE) (BD Pharmingen). Cells were stained according to the 
manufacturers protocols. GlyR α2 positive cells make up 30% of the total 
PBMC population. The T cell population (CD3+) accounts for more than 60% of 
the PBMC population and was mostly negative for GlyR α2 expression 
(A), whilst all of the monocyte population (CD14+) was positive for GlyR α2 
(B). More than half of the natural killer (NK) population (CD56+) was positive for 
GlyR α2 (C). However, since the T cell population was negative, it is likely that 
the NK T cells are also negative. Cells that were positive for both GlyR α2 and 
for the lineage specifi c cell surface marker appear in the top right hand side 
quadrant.
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renal ischemia (Yin et al., 2002). These effects might also be relevant 
under normal physiological conditions since when normal rats 
are infused with glycine, a decrease in renal vascular resistance is 
observed, leading to an increase in renal plasma fl ow and, hence, 
in GFR. In addition, glycine also decreases proximal tubular reab-
sorption (Thomsen et al., 2002).
CONCLUSION
Numerous in vitro and in vivo studies provide evidence for a cyto-
protective role of glycine against kidney ischemia. This effect seems 
to be mediated by GlyRs with unusual properties: (i) there is little 
evidence that GlyR α subunits are expressed in kidney cell types, 
(ii) glycine effects can be mimicked by both GlyR agonists and 
antagonists and (iii) these effects do not depend upon the chloride 
gradient. Currently, porous defects are thought to develop in plasma 
membranes of ischemic cells as a consequence of a molecular per-
turbation of GlyR channels, that lead to leakage of macromolecules 
and, hence, to cell death. Glycine and GlyR antagonists might stabi-
lize this unusual GlyR of unknown subunit composition accounting 
for cytoprotective effects.
HEPATOCYTES
In the liver, ischemia-reperfusion injury is a serious problem after 
liver transplantation that often leads to primary graft dysfunction. 
Thus, glycine is a potential cytoprotective agent of particular inter-
est for the liver. The specifi c role of glycine in hepatic ischemia-
reperfusion injury was recently reviewed (Habib et al., 2006). A few 
years after the fi rst report of a cytoprotective role of glycine in renal 
ischemia, Marsh and colleagues showed that isolated hepatocytes 
exposed to cold ischemia in the presence of glycine (3 mM) expe-
rienced a signifi cant improvement of cellular injury compared to 
controls (Marsh et al., 1991). This effect was shown to be inde-
pendent of glutathione synthesis (Marsh et al., 1991; Ozaki et al., 
1994). Comparable effects were observed with high concentrations 
of alanine (10 mM) and strychnine (1 mM) as well as under con-
ditions of metabolic inhibition (chemical hypoxia; Dickson et al., 
1992; Marsh et al., 1993; Nagatomi et al., 1997; Sakaida et al., 1996). 
Also for hepatocytes, the strychnine effects were shown to be specifi c 
(Dong et al., 2001). Glycine hepatoprotective effects were independ-
ent of ATP levels or intracellular acidosis, and glycine could not 
protect against injury caused by calcium ionophores or by oxidative 
stress (Marsh et al., 1993; Sakaida et al., 1996). It was also shown 
that glycine could inhibit calcium-dependent non-lysosomal pro-
tease activity during ischemia (Ferguson et al., 1993; Nichols et al., 
1994). High concentrations of glycine (2–10 mM), but also l-alanine 
(10 mM) or strychnine (1 mM), were shown to be protective and to 
non-specifi cally block infl ux of different ions (e.g. sodium, cobalt 
or nickel; Carini et al., 1997; Frank et al., 2000). Although it was 
shown that blocking sodium infl ux by itself was cytoprotective and 
was dependent upon chloride infl ux, glycine was still protective in a 
sodium- or chloride-free buffer. Glycine was hypothesized to block 
non-specifi c ‘leak’ channels, which might increase in number and 
permeability with time (Frank et al., 2000). Glycine protects hepato-
cytes form ischemic cell death, but it does not prevent the mitochon-
drial permeability transition (MPT), contrary to cellular acidosis 
or sodium-free culture conditions, both preventing the MPT (Qian 
et al., 1997). In a review on the role of the MPT in ischemic cell death 
was shown that this protection could be mimicked by  structurally 
related amino acids such as l-alanine (Weinberg et al., 1990b), 
that it was independent of ATP (Weinberg et al., 1997) or calcium 
(Venkatachalam et al., 1995; Weinberg et al., 1991b) and that it does 
not protect either against swelling of ischemic cells (Weinberg et al., 
1990a) or against plasma membrane breakdown (Venkatachalam 
et al., 1995). In comparable experimental paradigms, strychnine, 
in high concentrations (1 mM), was shown to act as an agonist, 
rather than an antagonist (Aleo and Schnellmann, 1992; Dong et al., 
2001). Other GlyR antagonists and chloride channel blockers (e.g. 
brucine, bicuculline, avermectin B1a, and cyanotriphenylborate) 
were also demonstrated to exert glycine-like activity (Miller and 
Schnellmann, 1994; Venkatachalam et al., 1996). Dong and col-
leagues investigated whether this strychnine protection was due to 
an (aspecifi c) intracellular interaction or to an interaction at the 
cellular membrane, as would be expected for ligand-gated  channel-
mediated actions. They showed that membrane-impermeable 
strychnine derivatives maintained their cytoprotective properties in 
MDCK (Madin–Darby canine kidney) cells, a distal tubular cell line. 
Moreover, they showed that small modifi cations to the molecule 
near the interacting centre for receptor binding abolished the effect 
(Dong et al., 2001). These results clearly prove specifi c strychnine 
interactions with surface-oriented extracellular domains. Although 
the effects of these compounds are typically receptor dependent, 
in renal cells these effects do not seem to depend on chloride ion 
gradients, since replacement of chloride by gluconate could not 
abolish the effects. In an attempt to explain this apparent con-
tradiction, it has been suggested that under ischemic conditions, 
dysregulation of GlyRs leads to the development of a pathological 
pore, allowing the penetration of macromolecules and, hence, cell 
death (Venkatachalam et al., 1996). This pore formation can be 
prevented by adding agonists as well as antagonists, which some-
how stabilize the GlyR. This hypothesis was supported by Dong 
and co-authors, who showed that, in ischemic conditions, there is 
a size- dependent membrane penetration of macromolecular dex-
trans, with a progressive increase in permeability for larger dextran 
molecules during the period of ischemia. This permeability defect 
could be prevented by a cross-linking agent (3,3′ dithiobis(sulfosuc-
cinimidylpropionate)) or by adding millimolar glycine (Dong et al., 
1998). Direct evidence for GlyR involvement was recently provided 
by a study that showed that inhibition of endogenous GlyR expres-
sion by RNA interference attenuates cytoprotection in MDCK cells 
(Pan et al., 2005). They also found that HEK (human embryonic 
kidney) cells were not protected from ischemic cell death by glycine, 
unless they were transfected with plasmid constructs expressing 
the GlyR α1 subunit. GlyR α1 mutants of Y202F or Y202L, which 
are shown to decrease glycine and strychnine binding, also specifi -
cally abolished the effects of glycine and strychnine, respectively, 
further suggesting the involvement of glycine receptor subunits 
in cytoprotection At the molecular level, most studies have only 
found evidence for GlyR β subunit and gephyrin expression at the 
basolateral membrane of proximal tubule cells (Grenningloh et al., 
1987; Miller and Schnellmann, 1994; Sarang et al., 1999). There is 
also in vivo evidence for a protective role of glycine against ischemic 
conditions in the kidney. For example, when rats were fed with a diet 
containing 5% glycine, their renal function was improved [higher 
glomerular fi ltration rate (GFR) and lower plasma  creatinine] after 
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of hepatocytes, it was argued that glycine acted downstream of the 
MPT, at a time point where cells are completely deprived of ATP 
and destined for necrotic cell death (Kim et al., 2003). Glycine was 
also shown to protect against hepatotoxicity induced by different 
agents (e.g. valproate, paracetamol, cadmium chloride or copper 
chloride), an effect that can only partly be explained by metabolic 
detoxifi cation of acyl-coenzyme A by means of acylglycine forma-
tion (Deters et al., 1998; Vance et al., 1994). To date, only one study 
has described clear GlyR-related modulatory effects in hepatocytes. 
Qu and colleagues demonstrated that glycine blocks prostaglandin 
E
2
- and epinephrine-induced calcium fl uxes in hepatocytes, an effect 
that is chloride-dependent and antagonized by low concentrations 
of strychnine (10 µM). However, no direct link between calcium 
modulation and cytoprotective effects could be made (Qu et al., 
2002). Molecular evidence for GlyRs in hepatocytes is scarce. A GlyR 
β subunit splice variant was described in liver homogenates (Oertel 
et al., 2007), but its cellular origin is unclear (hepatocytes, Kupffer 
cells or endothelial cells). To date, no GlyR α subunit gene expres-
sion has been described (Froh et al., 2002; Grenningloh et al., 1987). 
In vivo evidence also supports a protective role of glycine against 
liver ischemia and other pathologies. Several animal studies have 
shown that glycine has benefi cial effects during liver transplantation. 
When given intravenously to donors or when given to acceptors (den 
Butter et al., 1993; Ito et al., 2008; Schemmer et al., 1999), glycine 
improved survival and decreased liver enzyme concentrations. It is 
however noteworthy that besides a direct cytoprotective effect on 
hepatocytes, there is also an important immunomodulatory con-
tribution via the suppression of Kupffer cell activity in vivo. Indeed, 
a positive correlation was found between the protective effects of 
glycine and the decrease in Kupffer cell-derived TNFα and pro-
teases (Duenschede et al., 2006; Schemmer et al., 1999; Yamanouchi 
et al., 2007). Further evidence for Kupffer cell involvement in ben-
efi cial glycine effects came from an animal study that showed that 
glycine, when given to donors, decreases levels of TNFα and liver 
enzymes, an effect that can be blocked by adding low levels of strych-
nine (5 µM; Zhang et al., 2005). As strychnine antagonism is only 
established for immunomodulatory effects on Kupffer cells, but not 
for cytoprotective effects on hepatocytes, these fi ndings strongly 
support a crucial role for Kupffer cells. As mentioned earlier, ben-
efi cial effects of glycine in alcoholic liver disease were mainly due 
to Kupffer cells as well. Also in animal models of endotoxine and 
hemorrhagic shock, glycine modulation of Kupffer cells and inhibi-
tion of TNFα-secretion seem to be crucial for its benefi cial effects 
(Mauriz et al., 2001; Neyrinck et al., 2005; Wang et al., 2004; Yang 
et al., 2001; Zhong et al., 1999). On the other hand, it was shown 
that destruction of Kupffer cells by gadolinium chloride (GdCl) was 
far less potent than glycine in animal liver transplantation studies, 
suggesting that not all in vivo fi ndings can be explained by modu-
lation of Kupffer cells (Rentsch et al., 2002, 2005). Also, in animal 
models of cholestasis, where bile cannot fl ow from the liver to the 
duodenum it was shown that benefi cial glycine effects (lowering 
of TNFα levels, liver necrosis and liver enzymes) remained when 
Kupffer cells were destructed by GdCl (Fang et al., 2003; Froh et al., 
2008). Finally, some of the cytoprotective effects of glycine could 
also be attributed to glycine interacting with (sinusoidal) endothelial 
cells (see “Endothelial cells”). The above-mentioned cytoprotective 
effects of glycine against liver ischemia were  considered solid enough 
to trigger clinical trials. Preliminary studies with few patients were 
undertaken showing, in one fi rst study, that 2 mM glycine added to 
the perfusion solution during transplantation induced a signifi cant 
decrease in liver enzymes and evoked less complications (Arora et al., 
1999). A second study with seven patients confi rmed that a one-
week long daily infusion of glycine post-operatively (corresponding 
to ∼2 mM plasma concentration) signifi cantly decreased plasma 
liver enzyme levels (Schemmer et al., 2001, 2002). These preliminary 
results led to a multicenter, randomized, placebo-controlled double 
blind clinical trial that is currently under investigation (HEGPOL, 
“Hepatoprotective Effects of Glycine in the Postoperative Phase”; 
Luntz et al., 2005).
CONCLUSION
In the liver, glycine protects against ischemic injury what may have 
clinical applications to reduce complications in liver transplantation 
with preliminary clinical trials showing promising results. However, 
the molecular mechanism of the glycine effect remains elusive and 
nothing is known about the precise role or composition of hepatic 
GlyRs. As for the kidney, one hypothesis is that glycine could block 
non-specifi c pore formation, preventing plasma membrane leakage 
and, eventually, cell death. Besides direct cytoprotective effects on 
hepatocytes, glycine modulatory effects on Kupffer and endothelial 
cells have to be taken into account especially in in vivo studies.
ENDOTHELIAL CELLS
By analogy to the situation in the liver and in the kidney, glycine 
was also suggested to have cytoprotective effects in endothelial 
cells subjected to hypoxia or challenged with ionomycine, cyanide, 
hydrogen peroxide or maitotoxin (Estacion et al., 2003; Nishimura 
and Lemasters, 2001; Nishimura et al., 1998; Weinberg et al., 1992). 
These effects were independent of pH, ATP levels or calcium and 
could be mimicked by l-alanine. Estacion and co-workers found 
that glycine protective effects on cell death were taking place at 
the late phase of maitotoxin cytotoxicity and could prevent pore-
formation in the cytoplasmic membrane, which would normally 
lead to cell death. Nishimura and co-workers also hypothesized 
that glycine could block the opening of a “death channel” during 
hypoxia. They found that sinusoidal endothelial cells were going 
through different stages during ischemia. During early hypoxia, 
a cation infl ux appears as a consequence of a decrease in Na+/K+ 
ATPase activity. However, this is not accompanied by an anion 
infl ux and causes only moderate cell swelling. In a next stage, called 
the metastable state (characterized by the MPT), anions start fl ow-
ing inside cells through a “death channel” leading to an increase 
in colloid osmotic pressure, to bleb formation and, eventually, 
to the rupture of plasma membranes and to cell death. Based on 
the fi nding that glycine slows anionic calcein entrance, decreases 
bleb formation and prevents entrance of propidium iodide and 
macromolecules into cells, it was suggested that glycine could 
somehow inhibit this “death channel” (Nishimura and Lemasters, 
2001). Besides protecting against ischemic necrosis, glycine also 
seems to prevent apoptosis of sinusoidal endothelial cells induced 
by vascular endothelial growth factor (VEGF) deprivation. This 
protective effect is blocked by strychnine (1 µM) and is possibly 
mediated by enhanced bcl-2 expression (Zhang et al., 2000). In this 
context, VEGF-induced cellular calcium infl uxes can be completely 
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reaction, an indispensable step in the fertilization process. Glycine 
induces the acrosome reaction at micromolar concentrations and 
this effect can be blocked by very low concentrations of strychnine 
(50 nM). In the spasmodic and spastic mouse models (characterized 
by GlyR α1 and β subunit mutations, respectively), defi ciencies in 
the acrosome reaction are found. Molecular studies have detected 
GlyR α1, α3 and β subunits in the periacrosomal plasma membrane 
(Bray et al., 2002; Kumar and Meizel, 2008; Llanos et al., 2001, 2003; 
Meizel, 1997; Melendrez and Meizel, 1995, 1996; Sato et al., 2000a,b, 
2002). Interestingly, GlyR α4 subunit transcripts were also found 
in the male genital ridge in chicken (Harvey et al., 2000). Finally, 
cytoprotective effects of glycine in ischemia-reperfusion injury have 
also been described in other organs, such as in the gastro-intesti-
nal system, in skeletal muscle and the lungs (Ascher et al., 2001; 
Gohrbandt et al., 2006; Iijima et al., 1997; Lee et al., 2001, 2002; 
Mangino et al., 1996; Tariq and Al Moutaery, 1997). However, in 
those models, no clear cellular targets for glycine have been identi-
fi ed, so indirect effects via immune cells or even the nervous system 
have not been eliminated.
CONCLUSION
The effects of glycine, mediated by classical or unconventional 
GlyRs, have been described in many different non-neuronal cell 
types and both inside and outside the nervous system. Broadly, 
glycine effects can be classifi ed into two main types: cytoprotective 
and modulatory, an overview of which can be found in Table 1.
Modulatory effects of glycine were mainly found in immune cells 
such as macrophages and are associated with clear molecular and 
pharmacological evidence of functional GlyRs. For example, glycine 
in macrophages induces uptake of 36Cl− and inhibits calcium fl ux 
in a dose-dependent manner, in a concentration range of 0.1 and 
1 mM. Pharmacological fi ndings also support the involvement of 
GlyRs in these effects: blockage is observed by low concentrations 
of strychnine (1 µM), similar effects are elicited by taurine and β-
alanine, but not by l-alanine, and these effects are eliminated by 
replacement of chloride in buffers. At the molecular level, both GlyR 
α and β subunits have been described on these cells, although there 
may be important species differences. Besides immune cells, com-
parable modulatory effects were observed in glial cells, endothelial 
cells and spermatozoa. Although the GlyRs on these cells are clearly 
identical in subunit composition to selected neuronal GlyRs, it is 
remarkable that, to our knowledge, no direct electrophysiological 
evidence for functional GlyRs exists in immune cells. Although, tech-
nically, there is no problem performing patch-clamp experiments 
on these cells, the only non-neuronal cells where GlyR-mediated 
ionic currents have been directly measured are glial cells, and even in 
this case currents could only be recorded from spinal cord slices, as 
opposed to cultured cells. This suggests a complex regulation of GlyR 
expression in non-neuronal cells and further research is required to 
confi rm the existence of functional GlyRs on these cell types. In this 
regard, an emphasis on correct cell culture conditions may represent 
the best way forward. Cytoprotective effects were mainly studied in 
renal cells, hepatocytes and endothelial cells, and have obvious clini-
cal and therapeutic importance in the protection that is provided 
under ischemic conditions. There is some evidence linking these 
effects to GlyRs, although these receptors seem to function in an 
entirely different mode as described for the classic neuronal GlyRs. 
prevented by addition of 1 mM of glycine in CPA cells, a bovine 
endothelial cell line. This effect is clearly GlyR-dependent since it 
can be blocked by micromolar concentrations of strychnine and is 
eliminated in chloride-free buffer conditions. Furthermore, GlyR 
β subunit expression was found at the mRNA and protein level 
and glycine could decrease the proliferation and the migration of 
endothelial cells (Yamashina et al., 2001). This inhibiting effect of 
glycine on endothelial cells may explain why glycine was found to be 
tumour suppressive in melanoma and liver tumours. In this respect, 
it is of interest to mention that glycine inhibited tumour growth 
in the advanced stages only, which is when neo-angiogenesis has 
an important role in tumour progression because of oxygen need 
(Rose et al., 1999a,b). Later, it was demonstrated that glycine could 
indeed inhibit angiogenesis, leading to a decreased wound healing 
and tumour growth (Amin et al., 2003), suggesting that glycine 
effects on endothelial cells may be of future interest for research into 
atherosclerosis (McCarty et al., 2009). Glycine-mediated vascular 
effects were also attributed to NMDA receptors (NMDARs) in some 
studies. For example, Mishra and colleagues showed that glycine 
lowers the blood pressure in normotensive rats, while it increases 
it in hypertensive and l-NAME (NO synthase inhibitor)-treated 
rats. These effects were attributed to NMDAR activation on both 
endothelial and vascular smooth muscle cells, with the former being 
NO-dependent and prevailing under normotensive conditions and 
the latter prevailing under hypertensive conditions (Mishra et al., 
2008). NMDAR-mediated vascular effects were also suggested to 
mediate glycine vasodilatory effects and, hence, to increase GFR in 
the kidney (Deng et al., 2002; Slomowitz et al., 2004).
CONCLUSION
In endothelial cells, some modulating effects of glycine are present 
that appear to be mediated by GlyRs. Potential effects of glycine on 
migration and proliferation may explain benefi cial glycine effects 
on tumour growth and wound healing. As in the liver and in the 
kidney, some of the cytoprotective effects of glycine could be medi-
ated by a non-specifi c pore formed under ischemic conditions.
OTHER CELL TYPES
In cardiomyocytes, a few recent studies showed benefi cial glycine 
effects under ischemia-reperfusion conditions. For example, 3 mM 
glycine increases the cell viability of isolated cardiomyocytes and 
of isolated rat hearts after ischemia/reperfusion (Ruiz-Meana et al., 
2004). Based on the fi ndings that glycine prevented mitochondrial 
swelling and calcein release, it was suggested that glycine somehow 
inhibits the MPT. However, this contrasts with other fi ndings in the 
kidney and in the liver where the general assumption is that glycine 
acts downstream of the MPT (Kim et al., 2003). In another study, 
glycine infusion into animal donor hearts was benefi cial for right 
ventricular function after transplantation (Warnecke et al., 2006). 
Lastly, a recent study showed that 2 mM glycine could protect iso-
lated rat heart function and viability in an experimental LPS-induced 
decreased cardiac function model. This protective effect of glycine 
was linked to an attenuation of LPS- and hypoxia-induced calcium 
infl ux. Interestingly, the authors again detected the presence of GlyR 
β subunits, but not GlyR α subunits (Qi et al., 2007). GlyRs are also 
well described in sperm in humans, pigs, mice and golden hamsters 
where they are involved in the zona pellucida-initiated acrosome 
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Glycine effects also seem to be more non-specifi c in the sense that the 
observed effects can be mimicked by other structurally related amino 
acids (e.g. l-alanine) and are caused by higher concentrations of 
glycine (up to 10 mM). Other fi ndings inconsistent with GlyR-medi-
ated effects are the ‘agonist-like’ effects of strychnine in high con-
centrations (1 mM) and of non-specifi c chloride channel blockers, 
as well as the chloride-independent effects. At the molecular level, 
mainly GlyR β subunits have been detected, which are not reported 
to form functional homomeric GlyRs in recombinant systems. It is 
however noteworthy that the GlyR β subunit distribution in the CNS 
is far more extended compared to GlyR α subunits, suggesting that 
β subunits may have some as yet unknown function (Malosio et al., 
1991). The current hypothesis concerning the cytoprotective effects 
of glycine against ischemia is tenuous at best, since it requires the 
existence of a glycine-sensitive pore that is activated in later stages 
of ischemic cell death, leading to membrane leakage of macromol-
ecules. Moreover, this pore is stabilized and/or blocked by glycine, 
GlyR antagonists and some chloride blockers. Molecularly, this pore 
seems to be some multimeric protein, somehow associated with 
GlyR subunits which can stabilize the pore upon ligand binding. 
More research is certainly needed to further explore this intrigu-
ing hypothesis. Finally, when considering glycine-related effects in 
non-neuronal cells, it is important to realize that other mechanisms 
do exist, some of which maybe also important for the reported 
modulatory and cytoprotective effects, but fall beyond the scope of 
this review. These include the NMDAR-mediated glycine effect in 
the vascular system, transporter-mediated effects in microglial cells 
or possible metabolic effects in microglia or the liver.
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Table 1 | Most often evoked mechanisms responsible for glycine effects in non-neuronal cells.
 Cytoprotective effect Modulatory effect
Cells most studied Renal cells  Immune cells
 Hepatocytes Macroglial cells
 Endothelial cells Endothelial cells
Main effect Protection against ischemic necrosis Modulation of proliferation, migration, differentiation, 
  apoptosis,…
Active concentrations Up to 10 mM 0.1-1 mM
Calcium fl ux modulation No Yes
Uptake of 36-chloride No Yes
Chloride dependency No Yes
Pharmacological fi ndings No strychnine block described  Effects blocked by low concentrations of strychnine (1 µM) 
 Effects mimicked by structurally related  Effects mimicked by taurine and β-alanine
 amino acids (e.g. L-alanine, L-serine) 
 Effects mimicked by high concentrations (1 mM) 
 of strychnine and other chloride channel blockers 
 No mimicking by taurine
Molecular fi ndings Only β-subunits Both α- and β-subunits
Electrophysiological fi ndings None Only in slice preparations of macroglial cells
Suggested mechanism Glycine sensitive death pathway  GlyR dependent modulation of calcium signalling
 Unknown role of GlyR (subunit)s
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